These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16025226)

  • 1. Do standardized beta-blocker titration protocols in heart failure improve compliance? The GESICA registry experience.
    Remme WJ
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):99-101. PubMed ID: 16025226
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of a standardized titration protocol with carvedilol in heart failure: safety, tolerability, and efficacy-a report from the GESICA registry.
    Nul D; Zambrano C; Diaz A; Ferrante D; Varini S; Soifer S; Grancelli H; Doval H;
    Cardiovasc Drugs Ther; 2005 Mar; 19(2):125-34. PubMed ID: 16025231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. beta-blocker improvement in diastolic performance: the yin and yang of ventricular function changes.
    Eichhorn EJ; Grayburn PA
    Am Heart J; 2000 Apr; 139(4):584-6. PubMed ID: 10740138
    [No Abstract]   [Full Text] [Related]  

  • 4. Dismantling mandates in the treatment of heart failure.
    Leier CV
    J Am Coll Cardiol; 2004 Nov; 44(9):1831-3. PubMed ID: 15519015
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).
    Bergström A; Andersson B; Edner M; Nylander E; Persson H; Dahlström U
    Eur J Heart Fail; 2004 Jun; 6(4):453-61. PubMed ID: 15182771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
    Otterstad JE; Ford I
    Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with carvedilol.
    Moser M
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S16-20. PubMed ID: 8098064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heart failure symptoms despite normal pump function. Beta blockers also improve diastole].
    MMW Fortschr Med; 2003 Jun; 145(26):58. PubMed ID: 12916341
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure.
    Lou YF; Shi XP; Tong H; Yu GY; Yao GD; Dong K
    Circ J; 2009 Dec; 73(12):2363; author reply 2364. PubMed ID: 19940373
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left ventricular systolic dysfunction in a cardiac transplant recipient treated with carvedilol.
    Gardner RS; McGowan J; McDonagh TA
    Eur J Heart Fail; 2002 Jun; 4(3):377-9. PubMed ID: 12034165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure.
    Maurer MS; Sackner-Bernstein JD; El-Khoury Rumbarger L; Yushak M; King DL; Burkhoff D
    Circ Heart Fail; 2009 May; 2(3):189-96. PubMed ID: 19808339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hormonal hyperactivity in heart failure. Differences in beta blockers].
    Beuckelmann DJ
    Herz; 2002 Aug; 27 Suppl 1():9-15. PubMed ID: 12229258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Beta blocker for therapy of heart failure. Decreased mortality and fewer clinic admissions].
    Pickl S
    Fortschr Med; 1997 Apr; 115(11):22. PubMed ID: 9221239
    [No Abstract]   [Full Text] [Related]  

  • 16. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance.
    Metra M; Nodari S; Parrinello G; Giubbini R; Manca C; Dei Cas L
    Am Heart J; 2003 Feb; 145(2):292-9. PubMed ID: 12595847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does atrial fibrillation in very elderly patients with chronic systolic heart failure limit the use of carvedilol?
    Cioffi G; De Feo S; Pulignano G; Del Sindaco D; Tarantini L; Stefenelli C; Opasich C
    Int J Cardiol; 2006 Feb; 107(2):220-4. PubMed ID: 16412800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of carvedilol on exercise tolerance in patients with chronic heart failure and a restrictive left ventricular filling pattern.
    Al-Nasser F; Yousufuddin M; Al-Nozha F; Anker SD; Coats AJ; Piepoli MF; Ponikowski PP
    Am J Cardiol; 2003 May; 91(10):1281-3. PubMed ID: 12745124
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure.
    Podbregar M; Voga G
    J Card Fail; 2002 Dec; 8(6):369-78. PubMed ID: 12528088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Carvedilol in ischemic heart failure. Hibernating myocardium resuscitated].
    MMW Fortschr Med; 2003 Feb; 145(8):57. PubMed ID: 12661451
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.